Last reviewed · How we verify
NCT01310192
Cancer Localization in the Prostate With F-18 Fluorocholine Positron Emission Tomography
Phase 1 trial testing Fluourine-18 Fluoromethylcholine PET/CT Imaging in Prostate Cancer in 20 participants. Completed in 1 July 2008.
1 July 2008
Quick facts
| Lead sponsor | Queen's Medical Center |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 20 |
| Start date | 1 June 2004 |
| Primary completion | 1 July 2008 |
| Estimated completion | 1 July 2008 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Fluourine-18 Fluoromethylcholine PET/CT Imaging
Conditions studied
- Prostate Cancer — all drugs for Prostate Cancer →
Sponsor
Queen's Medical Center
Who can join
18 and older, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Histopathologic Diagnosis - sextant diagnosis by whole-prostate step section histopathologic analysis
Time frame: Immediate - no longitudinal data collected
Sponsor's own description
The purpose of this project is to develop and evaluate fluorine-18 (F-18) fluorocholine (FCH) positron emission tomography (PET) as an imaging technique that can be used to delineate malignant tumors in the prostate gland. The proposed technique works by measuring the tissue metabolism of FCH, a substrate that is preferentially metabolized by cancer cells due to malignant over-expression of the choline transporter and choline kinase enzyme. The project scope covers a clinical study to recruit men with prostate cancer who have elected treatment by radical prostatectomy surgery. These men will undergo pre-operative PET scanning to measure F-18 FCH uptake in anatomical sextants of the prostate gland. Imaging results will be compared to histopathologic analyses of the prostatectomy specimen to determine the accuracy of F-18 FCH PET for detecting cancerous prostate sextants.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT01310192
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Prostate Cancer
Currently open trials in the same condition.
- NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
- NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
- NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
- NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
- NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting
Other Queen's Medical Center trials
Trials by the same sponsor.
- NCT06931197 — Why Wait? Initiating Contingency Management in Traumatically Injured Patients During Hospitalization · NA · not yet recruiting
- NCT06933381 — Vapocoolant Spray to Reduce Pain With Nexplanon Insertion · NA · recruiting
- NCT06951438 — Assessing Acceptability and Feasibiity of STI Self-swab Testing, to be Offered at the Time of Telemed Medication Abortio · NA · recruiting
- NCT06532370 — Implementing a Contingency Management Program Addressing Methamphetamine Use For and With the People of Hawaii · NA · recruiting
- NCT06529003 — TENS Unit To Decrease Pain After Laminaria Insertion · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01310192 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Queen's Medical Center
- Last refreshed: 19 July 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01310192.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing